-
1
-
-
84925840665
-
Über das Zustandekommen der Diphterie- Immunität und der Tetanus-Immunität bei Thieren
-
Behring E, Kitasato S. Über das Zustandekommen der Diphterie- Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wschr 1890; 16:1113-1114.
-
(1890)
Dtsch Med Wschr
, vol.16
, pp. 1113-1114
-
-
Behring, E.1
Kitasato, S.2
-
2
-
-
0000419304
-
Agammaglobulinemia
-
Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9: 722-728.
-
(1952)
Pediatrics
, vol.9
, pp. 722-728
-
-
Bruton, O.C.1
-
3
-
-
0019463420
-
High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura
-
Imbach P, Barandun S, d'Apuzzo V, et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 1: 1228-1231.
-
(1981)
Lancet
, vol.1
, pp. 1228-1231
-
-
Imbach, P.1
Barandun, S.2
d'Apuzzo, V.3
-
4
-
-
33846080463
-
Drug insight: The use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues
-
Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3(1): 36-44.
-
(2007)
Nat Clin Pract Neurol
, vol.3
, Issue.1
, pp. 36-44
-
-
Gold, R.1
Stangel, M.2
Dalakas, M.C.3
-
5
-
-
72149111128
-
Intravenous immunoglobulins- understanding properties and mechanisms
-
Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins- understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl. 1): 2-13.
-
(2009)
Clin Exp Immunol
, vol.158
, Issue.SUPPL. 1
, pp. 2-13
-
-
Durandy, A.1
Kaveri, S.V.2
Kuijpers, T.W.3
-
7
-
-
78049515693
-
The new generation of liquid intravenous immunoglobulin formulations in patient care: A comparison of intravenous immunoglobulins
-
Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med 2010; 122: 176-184.
-
(2010)
Postgrad Med
, vol.122
, pp. 176-184
-
-
Stein, M.R.1
-
8
-
-
0042347801
-
Side effects of intravenous immunoglobulins in neurological autoimmune disorders a prospective study
-
Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders a prospective study. J Neurol 2003; 250: 818-821.
-
(2003)
J Neurol
, vol.250
, pp. 818-821
-
-
Stangel, M.1
Kiefer, R.2
Pette, M.3
-
9
-
-
0030069541
-
Complications of intravenous gammaglobulin in neuromuscular and other diseases
-
Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerv 1996; 19: 388-391.
-
(1996)
Muscle Nerv
, vol.19
, pp. 388-391
-
-
Bertorini, T.E.1
Nance, A.M.2
Horner, L.H.3
-
10
-
-
0029819741
-
Complications of intravenous immune globulin treatment in neurologic disease
-
Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47:674-677.
-
(1996)
Neurology
, vol.47
, pp. 674-677
-
-
Brannagan, T.H.1
Nagle, K.J.2
Lange, D.J.3
Rowland, L.P.4
-
11
-
-
0022626952
-
Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia
-
Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. N Engl J Med 314 1986; 314: 560-564.
-
(1986)
N Engl J Med
, vol.314
, Issue.314
, pp. 560-564
-
-
Burks, A.W.1
Sampson, H.A.2
Buckley, R.H.3
-
14
-
-
0028129450
-
Intravenous immunoglobulin-induced osmotic nephrosis
-
Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Int Med 1994; 154: 1985-1987.
-
(1994)
Arch Int Med
, vol.154
, pp. 1985-1987
-
-
Ahsan, N.1
Palmer, B.F.2
Wheeler, D.3
Greenlee Jr., R.G.4
Toto, R.D.5
-
15
-
-
0029902656
-
Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré-syndrome patient treated with intravenous immunoglobulin
-
Voltz R, Rosen FV, Yousry T, et al. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré-syndrome patient treated with intravenous immunoglobulin. Neurology 1996; 46: 250-251.
-
(1996)
Neurology
, vol.46
, pp. 250-251
-
-
Voltz, R.1
Rosen, F.V.2
Yousry, T.3
-
16
-
-
27744493135
-
Review: Intravenous immunoglobulin therapy and thromboembolic complications
-
Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802-808.
-
(2005)
Lupus
, vol.14
, pp. 802-808
-
-
Katz, U.1
Shoenfeld, Y.2
-
17
-
-
0028604458
-
Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors
-
Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-262.
-
(1994)
Ann Intern Med
, vol.121
, pp. 259-262
-
-
Sekul, E.A.1
Cupler, E.J.2
Dalakas, M.C.3
-
19
-
-
0030753782
-
Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases
-
Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerv 1997; 20:1102-1107.
-
(1997)
Muscle Nerv
, vol.20
, pp. 1102-1107
-
-
Koffman, B.M.1
Dalakas, M.C.2
-
20
-
-
51449103646
-
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
-
van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7: 939-950.
-
(2008)
Lancet Neurol
, vol.7
, pp. 939-950
-
-
van Doorn, P.A.1
Ruts, L.2
Jacobs, B.C.3
-
21
-
-
0026516454
-
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
-
Dutch Guillain-Barré-Study- Group
-
Van der Meche FGA, Schmitz PIM, Dutch Guillain-Barré-Study- Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
-
(1992)
N Engl J Med
, vol.326
, pp. 1123-1129
-
-
van der Meche, F.G.A.1
Schmitz, P.I.M.2
-
22
-
-
0030006629
-
Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré-Syndrome
-
Brill V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré-Syndrome. Neurology 1996; 46: 100-103.
-
(1996)
Neurology
, vol.46
, pp. 100-103
-
-
Brill, V.1
Ilse, W.K.2
Pearce, R.3
-
23
-
-
0031034253
-
Randomized trial of plasma exchange, intravenous immunoglobulins and combined treatments in Guillain-Barré syndrome
-
Plasma exchange/Sandoglobulin Guillain-Barré-Syndrom Trial Group
-
Plasma exchange/Sandoglobulin Guillain-Barré-Syndrom Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulins and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-230.
-
(1997)
Lancet
, vol.349
, pp. 225-230
-
-
-
24
-
-
0034913249
-
Intravenous immune globulins in patients with Guillain-Barré syndrom and contraindications to plasma exchange: 3 days versus 6 days
-
Rafael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barré syndrom and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg and Psychiatry 2001; 71: 235-238.
-
(2001)
J Neurol Neurosurg and Psychiatry
, vol.71
, pp. 235-238
-
-
Rafael, J.C.1
Chevret, S.2
Harboun, M.3
-
25
-
-
0029130630
-
Guillain- Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features
-
Dutch Guillain-Barré Study Group
-
Visser LH, van der Meche FGA, van Doorn PA, et al. Guillain- Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995; 118: 841-847.
-
(1995)
Brain
, vol.118
, pp. 841-847
-
-
Visser, L.H.1
van der Meche, F.G.A.2
van Doorn, P.A.3
-
26
-
-
0031768424
-
Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Plasma exchange / Sandoglobuline Guillain-Barré Syndrome Trial Group
-
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange / Sandoglobuline Guillain-Barré Syndrome Trial Group. Ann Neurol 1998; 44: 780-788.
-
(1998)
Ann Neurol
, vol.44
, pp. 780-788
-
-
Hadden, R.D.1
Cornblath, D.R.2
Hughes, R.A.3
-
27
-
-
1642452717
-
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomized trial
-
van Koningsveld R, Schmitz PIM, van der Meche FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomized trial. Lancet 2004; 363: 192-196.
-
(2004)
Lancet
, vol.363
, pp. 192-196
-
-
van Koningsveld, R.1
Schmitz, P.I.M.2
van der Meche, F.G.A.3
-
28
-
-
85058198416
-
Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome
-
Korinthenberg R. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1998; 2: 57-59.
-
(1998)
Eur J Paediatr Neurol
, vol.2
, pp. 57-59
-
-
Korinthenberg, R.1
-
29
-
-
34548228508
-
Immunotherapy for Guillain-Barré syndrome: A systematic review
-
Hughes RAC, Swan AV, Raphael J-C, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130: 2245-2257.
-
(2007)
Brain
, vol.130
, pp. 2245-2257
-
-
Hughes, R.A.C.1
Swan, A.V.2
Raphael, J.-C.3
-
31
-
-
10744231704
-
Practice parameter: Immunnotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology
-
Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: Immunnotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-740.
-
(2003)
Neurology
, vol.61
, pp. 736-740
-
-
Hughes, R.A.C.1
Wijdicks, E.F.M.2
Barohn, R.3
-
32
-
-
84872196112
-
An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)
-
Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65.
-
(1956)
N Engl J Med
, vol.255
, pp. 57-65
-
-
Fisher, M.1
-
33
-
-
34147109701
-
Intravenous immunoglobulin therapy for Miller-Fisher syndrome
-
Mori M, Kuwabara S, Fukutake T, Hattori T Intravenous immunoglobulin therapy for Miller-Fisher syndrome. Neurology 2007; 68: 1144-1146.
-
(2007)
Neurology
, vol.68
, pp. 1144-1146
-
-
Mori, M.1
Kuwabara, S.2
Fukutake, T.3
Hattori, T.4
-
34
-
-
41149148901
-
Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders
-
Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007; CD004761.
-
(2007)
Cochrane Database Syst Rev
-
-
Overell, J.R.1
Hsieh, S.T.2
Odaka, M.3
-
35
-
-
33644747705
-
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
-
Hughes RAC, Allen D, Makowska A, et al. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006; 11: 30-46.
-
(2006)
J Peripher Nerv Syst
, vol.11
, pp. 30-46
-
-
Hughes, R.A.C.1
Allen, D.2
Makowska, A.3
-
36
-
-
0029776819
-
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study
-
Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077.
-
(1996)
Brain
, vol.119
, pp. 1067-1077
-
-
Hahn, A.F.1
Bolton, C.F.2
Zochodne, D.3
-
37
-
-
0034899193
-
Randomized controlled trial of intravenous immunoglobulin (IVIg) versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy
-
Hughes RAC, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin (IVIg) versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201.
-
(2001)
Ann Neurol
, vol.50
, pp. 195-201
-
-
Hughes, R.A.C.1
Bensa, S.2
Willison, H.3
-
38
-
-
0035957105
-
Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy
-
Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449.
-
(2001)
Neurology
, vol.56
, pp. 445-449
-
-
Mendell, J.R.1
Barohn, R.J.2
Freimer, M.L.3
-
39
-
-
0025343185
-
High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study
-
van Doorn PA, Brand A, Strengers PFW, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209-212.
-
(1990)
Neurology
, vol.40
, pp. 209-212
-
-
van Doorn, P.A.1
Brand, A.2
Strengers, P.F.W.3
-
40
-
-
0027535214
-
Intravenous immunoglobuline treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study
-
Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobuline treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg und Psychiatry 1993; 56: 36-39.
-
(1993)
J Neurol Neurosurg Und Psychiatry
, vol.56
, pp. 36-39
-
-
Vermeulen, M.1
van Doorn, P.A.2
Brand, A.3
-
41
-
-
38349038052
-
Intravenous immunoglobulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial
-
Hughes RAC, Donofrio P, Bril V, et al. Intravenous immunoglobulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144.
-
(2008)
Lancet Neurol
, vol.7
, pp. 136-144
-
-
Hughes, R.A.C.1
Donofrio, P.2
Bril, V.3
-
42
-
-
65649103713
-
Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV
-
Bril V, Katzberg H, Donofrio P, et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009; 39: 448-455.
-
(2009)
Muscle Nerve
, vol.39
, pp. 448-455
-
-
Bril, V.1
Katzberg, H.2
Donofrio, P.3
-
43
-
-
65349156859
-
Health-related quality-oflife improvements in CIDP with immune globulin IV 10%: The ICE study
-
Merkies ISJ, Bril V, Dalakas MC, et al. Health-related quality-oflife improvements in CIDP with immune globulin IV 10%: The ICE study. Neurology 2009; 72: 1337-1344.
-
(2009)
Neurology
, vol.72
, pp. 1337-1344
-
-
Merkies, I.S.J.1
Bril, V.2
Dalakas, M.C.3
-
44
-
-
33750896818
-
Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy
-
Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv System 2006; 11: 325-329.
-
(2006)
J Peripher Nerv System
, vol.11
, pp. 325-329
-
-
Rajabally, Y.A.1
Seow, H.2
Wilson, P.3
-
45
-
-
33748971878
-
Immunoglobulins - basic considerations
-
Mix E, Goertsches R, Zettl UK. Immunoglobulins - basic considerations. J Neurol 2006; 253(Suppl 5): 9-17.
-
(2006)
J Neurol
, vol.253
, Issue.SUPPL. 5
, pp. 9-17
-
-
Mix, E.1
Goertsches, R.2
Zettl, U.K.3
-
46
-
-
20244377672
-
Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP
-
Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 2005; 64: 1471-1475.
-
(2005)
Neurology
, vol.64
, pp. 1471-1475
-
-
Iijima, M.1
Yamamoto, M.2
Hirayama, M.3
-
47
-
-
34248139668
-
Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy
-
Tackenberg B, Lünemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68: 1622-1629.
-
(2007)
Neurology
, vol.68
, pp. 1622-1629
-
-
Tackenberg, B.1
Lünemann, J.D.2
Steinbrecher, A.3
-
48
-
-
49549114260
-
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases
-
Elovaara I, Apostolski S, Doorn P van, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15: 893-908.
-
(2008)
Eur J Neurol
, vol.15
, pp. 893-908
-
-
Elovaara, I.1
Apostolski, S.2
van Doorn, P.3
-
49
-
-
33646035214
-
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society
-
Hughes RAC, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332.
-
(2006)
Eur J Neurol
, vol.13
, pp. 326-332
-
-
Hughes, R.A.C.1
Bouche, P.2
Cornblath, D.R.3
-
50
-
-
27644516384
-
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society
-
Joint task force of the EFNS and PNS
-
Joint task force of the EFNS and PNS, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005; 10: 220-228.
-
(2005)
J Peripher Nerv Syst
, vol.10
, pp. 220-228
-
-
-
51
-
-
70249146129
-
Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy
-
Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy. Cochrane Database Syst Rev 2009; CD001797.
-
(2009)
Cochrane Database Syst Rev
-
-
Eftimov, F.1
Winer, J.B.2
Vermeulen, M.3
-
52
-
-
58249094590
-
Intravenous immunoglobulin is effective in patiens with diabetes and with chronic inflammatory demyelinating polyneuropathy: Long term follow-up
-
Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patiens with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 2009; 80: 70-73.
-
(2009)
J Neurol Neurosurg Psychiatry
, vol.80
, pp. 70-73
-
-
Jann, S.1
Bramerio, M.A.2
Facchetti, D.3
Sterzi, R.4
-
53
-
-
0034160485
-
Important drug warning: Acute renal failure associated with immune globulin intravenous (human)
-
Epstein JS, Zoon KC. Important drug warning: acute renal failure associated with immune globulin intravenous (human). Neonatal Netw 2000, 19: 60-62.
-
(2000)
Neonatal Netw
, vol.19
, pp. 60-62
-
-
Epstein, J.S.1
Zoon, K.C.2
-
54
-
-
77956384856
-
Correlates of outcome and response to IVIg in 88 patients with multifocal motorneuropathy
-
Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motorneuropathy. Neurology 2010; 75: 818-825.
-
(2010)
Neurology
, vol.75
, pp. 818-825
-
-
Cats, E.A.1
van der Pol, W.L.2
Piepers, S.3
-
55
-
-
0028330355
-
Intravenous immunoglobulin treatment in patients with motoneuron syndromes associated with anti-GM1-antibodies: A double-blind, placebo-controlled study
-
Azulay J-P, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motoneuron syndromes associated with anti-GM1-antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44: 429-432.
-
(1994)
Neurology
, vol.44
, pp. 429-432
-
-
Azulay, J.-P.1
Blin, O.2
Pouget, J.3
-
56
-
-
0034649381
-
Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebocontrolled study
-
Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebocontrolled study. Neurology 2000; 55: 1256-1262.
-
(2000)
Neurology
, vol.55
, pp. 1256-1262
-
-
Federico, P.1
Zochodne, D.W.2
Hahn, A.F.3
-
57
-
-
0035182250
-
Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double blind, placebo-controlled study
-
Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double blind, placebo-controlled study. Brain 2001; 124: 145-153.
-
(2001)
Brain
, vol.124
, pp. 145-153
-
-
Leger, J.M.1
Chassande, B.2
Musset, L.3
-
58
-
-
0029114530
-
Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study
-
Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59: 248-252.
-
(1995)
J Neurol Neurosurg Psychiatry
, vol.59
, pp. 248-252
-
-
van den Berg, L.H.1
Kerkhoff, H.2
Oey, P.L.3
-
59
-
-
37749024424
-
Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: A retrospective study of response to IVIg and of its predictive criteria in 40 patients
-
Leger J-M, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008; 79: 93-96.
-
(2008)
J Neurol Neurosurg Psychiatry
, vol.79
, pp. 93-96
-
-
Leger, J.-M.1
Viala, K.2
Cancalon, F.3
-
60
-
-
1342266965
-
How long is IVIg effective in multifocal motor neuropathy?
-
Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology 2004; 62: 666-668.
-
(2004)
Neurology
, vol.62
, pp. 666-668
-
-
Terenghi, F.1
Cappellari, A.2
Bersano, A.3
-
61
-
-
5344241214
-
Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg
-
Vucic S, Black KR, Siao Tick Chong P, Cros D. Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004; 63: 1264-1269.
-
(2004)
Neurology
, vol.63
, pp. 1264-1269
-
-
Vucic, S.1
Black, K.R.2
Siao, T.C.P.3
Cros, D.4
-
62
-
-
33747728774
-
Multifocal motor neuropathy with and without conduction block: A single entity?
-
Delmont E, Azulay JP, Giorgi R, et al. Multifocal motor neuropathy with and without conduction block: A single entity? Neurology 2006; 67: 592-596.
-
(2006)
Neurology
, vol.67
, pp. 592-596
-
-
Delmont, E.1
Azulay, J.P.2
Giorgi, R.3
-
63
-
-
23944435632
-
A practical definition of conduction block in IvIg responsive multifocal motor neuropathy
-
Ghosh A, Busby M, Kennett R, et al. A practical definition of conduction block in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2005; 76: 1264-1268.
-
(2005)
J Neurol Neurosurg Psychiatry
, vol.76
, pp. 1264-1268
-
-
Ghosh, A.1
Busby, M.2
Kennett, R.3
-
64
-
-
36049004864
-
Multifocal motor neuropathy: The diagnostic spectrum and response to treatment
-
Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: The diagnostic spectrum and response to treatment. Neurology 2007; 69: 1680-1687.
-
(2007)
Neurology
, vol.69
, pp. 1680-1687
-
-
Slee, M.1
Selvan, A.2
Donaghy, M.3
-
65
-
-
33645238577
-
Prediction of response to IVIg treatment in patients with lower motor neurone disorders
-
Strigl-Pill N, König A, Schröder M, et al. Prediction of response to IVIg treatment in patients with lower motor neurone disorders. Eur J Neurol 2006; 13: 135-140.
-
(2006)
Eur J Neurol
, vol.13
, pp. 135-140
-
-
Strigl-Pill, N.1
König, A.2
Schröder, M.3
-
66
-
-
34547800216
-
Mycophenolate mofetil as adjunctive therapy for MMN patients: A randomized controlled trial
-
Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized controlled trial. Brain 2007; 130: 2004-2010.
-
(2007)
Brain
, vol.130
, pp. 2004-2010
-
-
Piepers, S.1
van den Berg-Vos, R.2
van der Pol, W.-L.3
-
67
-
-
10444237417
-
Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg
-
Rüegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004; 63: 2178-2179.
-
(2004)
Neurology
, vol.63
, pp. 2178-2179
-
-
Rüegg, S.J.1
Fuhr, P.2
Steck, A.J.3
-
69
-
-
64149091142
-
Subcutaneous versus intravenous immunoglobulin in multifocal neuropathy: A randomized, single-blinded, cross-over trial
-
Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal neuropathy: a randomized, single-blinded, cross-over trial. Eur J Neurol 2009; 16: 631-638.
-
(2009)
Eur J Neurol
, vol.16
, pp. 631-638
-
-
Harbo, T.1
Andersen, H.2
Hess, A.3
-
70
-
-
33845637319
-
Subcutaneous selfinfusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies
-
Köller H, Schroeter M, Feischen H, et al. Subcutaneous selfinfusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies, J Neurol 2006; 253: 1505-1506.
-
(2006)
J Neurol
, vol.253
, pp. 1505-1506
-
-
Köller, H.1
Schroeter, M.2
Feischen, H.3
-
71
-
-
33644749609
-
European Federation of Neurological Societies/Peripheral Nerve Society guidelines on management of multifocal motor neuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society
-
Joint task force for the EFNS and the PNS
-
Joint task force for the EFNS and the PNS, European Federation of Neurological Societies/Peripheral Nerve Society guidelines on management of multifocal motor neuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006; 11: 1-8.
-
(2006)
J Peripher Nerv Syst
, vol.11
, pp. 1-8
-
-
-
72
-
-
56349088280
-
New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: A prospective study of efficacy, safety and tolerability
-
Cats, EA, van der Pol WL, Piepers S, et al. New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: A prospective study of efficacy, safety and tolerability. J Neurol 2008; 255: 1598-1599.
-
(2008)
J Neurol
, vol.255
, pp. 1598-1599
-
-
Cats, E.A.1
van der Pol, W.L.2
Piepers, S.3
-
73
-
-
0036094478
-
Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy
-
Gorson KC, Ropper AH, Weinberg DH, et al. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 2002; 59: 766-772.
-
(2002)
Arch Neurol
, vol.59
, pp. 766-772
-
-
Gorson, K.C.1
Ropper, A.H.2
Weinberg, D.H.3
-
74
-
-
18644363004
-
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy
-
Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249: 1370-1377.
-
(2002)
J Neurol
, vol.249
, pp. 1370-1377
-
-
Comi, G.1
Roveri, L.2
Swan, A.3
-
75
-
-
0029852729
-
A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy
-
Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996; 40: 792-795.
-
(1996)
Ann Neurol
, vol.40
, pp. 792-795
-
-
Dalakas, M.C.1
Quarles, R.H.2
Farrer, R.G.3
-
76
-
-
8544267922
-
A randomised trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM
-
Mariette X, Chastang C, Clavelou P, et al. A randomised trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997; 63: 28-34.
-
(1997)
J Neurol Neurosurg Psychiatry
, vol.63
, pp. 28-34
-
-
Mariette, X.1
Chastang, C.2
Clavelou, P.3
-
77
-
-
0025355026
-
High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy
-
Cook D, Dalakas M, Galdi A, et al. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40: 212-214.
-
(1990)
Neurology
, vol.40
, pp. 212-214
-
-
Cook, D.1
Dalakas, M.2
Galdi, A.3
-
78
-
-
85047680478
-
Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy
-
Leger JM, Ben-Younes-Chennoufi A, Chassande B, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994; 57(Suppl): 46-49.
-
(1994)
J Neurol Neurosurg Psychiatry
, vol.57
, Issue.SUPPL.
, pp. 46-49
-
-
Leger, J.M.1
Ben-Younes-Chennoufi, A.2
Chassande, B.3
-
79
-
-
0030307620
-
Peripheral neuropathy associated with monoclonal IGG of undetermined significance: Clinical, electrophysiologic, pathologic and therapeutic study of 14 cases
-
Hermosilla E, Lagueny A, Vital C, et al. Peripheral neuropathy associated with monoclonal IGG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Peripher Nerv Syst 1996 1: 139-148.
-
(1996)
J Peripher Nerv Syst
, vol.1
, pp. 139-148
-
-
Hermosilla, E.1
Lagueny, A.2
Vital, C.3
-
81
-
-
0027393144
-
Polyneuropathy associated with IgA monoclonal gammopathy undetermined significance
-
Simmons Z, Bromberg MB, Feldman EL, et al. Polyneuropathy associated with IgA monoclonal gammopathy undetermined significance. Muscle Nerv 1993; 16: 77-83.
-
(1993)
Muscle Nerv
, vol.16
, pp. 77-83
-
-
Simmons, Z.1
Bromberg, M.B.2
Feldman, E.L.3
-
82
-
-
78650172976
-
Inflammation, demyelination, and degeneration - Recent insights from MS pathology
-
Stadelmann C, Wegner C, Brück W. Inflammation, demyelination, and degeneration - Recent insights from MS pathology. Biochim Biophys Acta 2011; 1812: 275-282.
-
(2011)
Biochim Biophys Acta
, vol.1812
, pp. 275-282
-
-
Stadelmann, C.1
Wegner, C.2
Brück, W.3
-
83
-
-
0034955141
-
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis
-
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
-
(2001)
Ann Neurol
, vol.50
, pp. 121-127
-
-
McDonald, W.I.1
Compston, A.2
Edan, G.3
-
84
-
-
28544436950
-
Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria
-
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
-
(2005)
Ann Neurol
, vol.58
, pp. 840-846
-
-
Polman, C.H.1
Reingold, S.C.2
Edan, G.3
-
85
-
-
79952501096
-
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
-
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
-
(2011)
Ann Neurol
, vol.69
, pp. 292-302
-
-
Polman, C.H.1
Reingold, S.C.2
Banwell, B.3
-
86
-
-
0029913882
-
Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Board on Clinical Trials of New Agents in Multiple Sclerosis
-
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Board on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
-
(1996)
Neurology
, vol.46
, pp. 907-911
-
-
Lublin, F.D.1
Reingold, S.C.2
-
87
-
-
84874018127
-
Immune-mediated CNS diseases: A review on nosological classification and clinical features
-
2011 May 18 [Epub ahead of print
-
Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2011 May 18 [Epub ahead of print].
-
Autoimmun Rev
-
-
Zettl, U.K.1
Stüve, O.2
Patejdl, R.3
-
88
-
-
81555223904
-
Autoimmune disorders affecting both the central and peripheral nervous system
-
2011 May 18. [Epub ahead of print]
-
Kamm C, Zettl UK. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 2011 May 18. [Epub ahead of print].
-
Autoimmun Rev
-
-
Kamm, C.1
Zettl, U.K.2
-
89
-
-
56349150992
-
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
-
Multiple Sclerosis Therapy Consensus Group (MSTCG)
-
Multiple Sclerosis Therapy Consensus Group (MSTCG). Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-1463.
-
(2008)
J Neurol
, vol.255
, pp. 1449-1463
-
-
Wiendl, H.1
Toyka, K.V.2
Rieckmann, P.3
-
90
-
-
33749363907
-
Symptomatic treatment of multiple sclerosis. Multiple Scerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society
-
Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society
-
Henze T, Rieckmann P, Toyka KV. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Scerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006; 56: 78-105.
-
(2006)
Eur Neurol
, vol.56
, pp. 78-105
-
-
Henze, T.1
Rieckmann, P.2
Toyka, K.V.3
-
91
-
-
5344219614
-
Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebocontrolled trial
-
Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebocontrolled trial. Arch Neurol 2004; 61: 1515-1520.
-
(2004)
Arch Neurol
, vol.61
, pp. 1515-1520
-
-
Achiron, A.1
Kishner, I.2
Sarova-Pinhas, I.3
-
92
-
-
0021035886
-
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
-
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
-
(1983)
Neurology
, vol.33
, pp. 1444-1452
-
-
Kurtzke, J.F.1
-
93
-
-
0036835646
-
Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: A metaanalysis
-
Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a metaanalysis. Eur J Neurol 2002; 9: 557-563.
-
(2002)
Eur J Neurol
, vol.9
, pp. 557-563
-
-
Sorensen, P.S.1
Fazekas, F.2
Lee, M.3
-
94
-
-
25844440884
-
Intravenous immunoglobulins in the treatment of relapsing-remitting multiple sclerosis- results of a retrospective multicenter observational study over five years
-
Haas J, Maas-Enriquez M, Hartung H-P. Intravenous immunoglobulins in the treatment of relapsing-remitting multiple sclerosis- results of a retrospective multicenter observational study over five years. Mult Scler 2005; 11: 562-567.
-
(2005)
Mult Scler
, vol.11
, pp. 562-567
-
-
Haas, J.1
Maas-Enriquez, M.2
Hartung, H.-P.3
-
95
-
-
50549098795
-
Intravenous immunglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial
-
Fazekas F, Lublin FD, Lee D, et al. Intravenous immunglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71: 265-271.
-
(2008)
Neurology
, vol.71
, pp. 265-271
-
-
Fazekas, F.1
Lublin, F.D.2
Lee, D.3
-
96
-
-
0027198554
-
Immunologically active proteins in intravenous immunoglobulin
-
Lam L, Whitsett CF, McNicholl JM, et al. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678.
-
(1993)
Lancet
, vol.342
, pp. 678
-
-
Lam, L.1
Whitsett, C.F.2
McNicholl, J.M.3
-
97
-
-
33644540149
-
Albumin and amino acids upregulate the expression of human beta-defensin 1
-
Sherman H, Chapnik N, Froy O. Albumin and amino acids upregulate the expression of human beta-defensin 1. Mol Immunol 2006; 43: 1617-1623.
-
(2006)
Mol Immunol
, vol.43
, pp. 1617-1623
-
-
Sherman, H.1
Chapnik, N.2
Froy, O.3
-
98
-
-
37249076371
-
Evaluation of inhibitory effects of human serum components on bactericidal activity of human betadefensin 3
-
Maisetta G, Di Luca M, Esin S, et al. Evaluation of inhibitory effects of human serum components on bactericidal activity of human betadefensin 3. Peptides 2008; 29: 1-6.
-
(2008)
Peptides
, vol.29
, pp. 1-6
-
-
Maisetta, G.1
Di Luca, M.2
Esin, S.3
-
99
-
-
79955774823
-
Administration of intravenous immunoglobulin in neurology: An evidenced based consensus: Update 2010
-
Stangl M, Gold R. Administration of intravenous immunoglobulin in neurology: an evidenced based consensus: update 2010. Nervenarzt 2011; 82: 415-430.
-
(2011)
Nervenarzt
, vol.82
, pp. 415-430
-
-
Stangl, M.1
Gold, R.2
-
100
-
-
4644250609
-
Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomized, placebo-controlled trial
-
Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomized, placebo-controlled trial. Lancet 2004; 364: 1149-1156.
-
(2004)
Lancet
, vol.364
, pp. 1149-1156
-
-
Hommes, O.R.1
Sorensen, P.S.2
Fazekas, F.3
-
101
-
-
39549098027
-
Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: A randomized placebo controlled multicenter study
-
Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicenter study. Mult Scler 2007; 13: 1107-1117.
-
(2007)
Mult Scler
, vol.13
, pp. 1107-1117
-
-
Pöhlau, D.1
Przuntek, H.2
Sailer, M.3
-
102
-
-
0032581445
-
Rate of pregnancy- related relapse in multiple sclerosis
-
Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy- related relapse in multiple sclerosis. N Engl J Med 1998; 339: 285-291.
-
(1998)
N Engl J Med
, vol.339
, pp. 285-291
-
-
Confavreux, C.1
Hutchinson, M.2
Hours, M.M.3
-
104
-
-
0033763213
-
High dose IVIg in the post partum period for prevention of exacerbations in MS
-
Haas J. High dose IVIg in the post partum period for prevention of exacerbations in MS. Mult Scler 2000; 6(Suppl 2): S18-S20.
-
(2000)
Mult Scler
, vol.6
, Issue.SUPPL. 2
-
-
Haas, J.1
-
105
-
-
4644350358
-
Effect of intravenous immunoglobuline treatment on pregnancy and post-partum related relapses in multiple sclerosis
-
Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobuline treatment on pregnancy and post-partum related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-1137.
-
(2004)
J Neurol
, vol.251
, pp. 1133-1137
-
-
Achiron, A.1
Kishner, I.2
Dolev, M.3
-
107
-
-
35848956089
-
A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis
-
Hass J, Hommes OR. A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 900-908.
-
(2007)
Mult Scler
, vol.13
, pp. 900-908
-
-
Hass, J.1
Hommes, O.R.2
-
108
-
-
68549107984
-
Exclusive breastfeeding und the risk of postpartum relapses in women with multiple sclerosis
-
Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding und the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66: 958-963.
-
(2009)
Arch Neurol
, vol.66
, pp. 958-963
-
-
Langer-Gould, A.1
Huang, S.M.2
Gupta, R.3
-
109
-
-
10444221955
-
IV immunoglobulins as add-on-treatment to methylprednisolone for acute relapses in MS
-
Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on-treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63: 2028-2033.
-
(2004)
Neurology
, vol.63
, pp. 2028-2033
-
-
Sorensen, P.S.1
Haas, J.2
Sellebjerg, F.3
-
110
-
-
0347337774
-
A randomized, doubleblind, placebo-controlled pilot study of i.v. immune globulins in combination i.v. methylprednisolone in the treatment of relapses in patients with MS
-
Visser LH, Beekman R, Tijssen CC, et al. A randomized, doubleblind, placebo-controlled pilot study of i.v. immune globulins in combination i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10: 89-91.
-
(2004)
Mult Scler
, vol.10
, pp. 89-91
-
-
Visser, L.H.1
Beekman, R.2
Tijssen, C.C.3
-
111
-
-
14644430331
-
A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis
-
Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810.
-
(2005)
Neurology
, vol.64
, pp. 804-810
-
-
Roed, H.G.1
Langkilde, A.2
Sellebjerg, F.3
-
112
-
-
53549104740
-
Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulins
-
Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulins. Eur J Neurol 2008; 15: 1163-1167.
-
(2008)
Eur J Neurol
, vol.15
, pp. 1163-1167
-
-
Tselis, A.1
Perumal, J.2
Caon, C.3
-
113
-
-
0032758846
-
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
-
Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
-
(1999)
Ann Neurol
, vol.46
, pp. 878-886
-
-
Weinshenker, B.G.1
O'Brien, P.C.2
Petterson, T.M.3
-
114
-
-
0035849518
-
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
-
Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
-
(2001)
Neurology
, vol.56
, pp. 1514-1522
-
-
Noseworthy, J.H.1
O'Brien, P.C.2
Petterson, T.M.3
-
115
-
-
0034711155
-
IV immunoglobulin does not reverse established weakness in MS. A doubleblind, placebo-controlled trial
-
Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. A doubleblind, placebo-controlled trial. Neurology 2000; 55: 1135-1143.
-
(2000)
Neurology
, vol.55
, pp. 1135-1143
-
-
Noseworthy, J.H.1
O'Brien, P.C.2
Weinshenker, B.G.3
-
116
-
-
0034104407
-
A placebo-controlled pilot trial to study the remyelinating potential of intravenous imunoglobulins in multiple sclerosis
-
Stangel M, Boegner F, Klatt CH, et al. A placebo-controlled pilot trial to study the remyelinating potential of intravenous imunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatriy 2000; 68: 89-92.
-
(2000)
J Neurol Neurosurg Psychiatriy
, vol.68
, pp. 89-92
-
-
Stangel, M.1
Boegner, F.2
Klatt, C.H.3
-
117
-
-
33745334334
-
Revised diagnostic criteria for neuroyelitis optica
-
Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuroyelitis optica. Neurology 2006; 66: 1485-1489.
-
(2006)
Neurology
, vol.66
, pp. 1485-1489
-
-
Wingerchuk, D.M.1
Lennon, V.A.2
Pittock, S.J.3
-
118
-
-
23944444890
-
IgG Marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel
-
Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG Marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
-
(2005)
J Exp Med
, vol.202
, pp. 473-477
-
-
Lennon, V.A.1
Kryzer, T.J.2
Pittock, S.J.3
-
119
-
-
34247534141
-
Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica
-
Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 4: 133.
-
(2007)
PLoS Med
, vol.4
, pp. 133
-
-
Paul, F.1
Jarius, S.2
Aktas, O.3
-
120
-
-
16844366404
-
An open label study of the effects of rituximab in neuromyelitis optica
-
Cree BAC, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
-
(2005)
Neurology
, vol.64
, pp. 1270-1272
-
-
Cree, B.A.C.1
Lamb, S.2
Morgan, K.3
-
121
-
-
55949127730
-
Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients
-
Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
-
(2008)
Arch Neurol
, vol.65
, pp. 1443-1448
-
-
Jacob, A.1
Weinshenker, B.G.2
Violich, I.3
-
122
-
-
0031665071
-
Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine
-
Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219-1220.
-
(1998)
Neurology
, vol.51
, pp. 1219-1220
-
-
Mandler, R.N.1
Ahmed, W.2
Dencoff, J.E.3
-
123
-
-
33745858352
-
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)
-
Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-963.
-
(2006)
Arch Neurol
, vol.63
, pp. 957-963
-
-
Weinstock-Guttman, B.1
Ramanathan, M.2
Lincoff, N.3
-
124
-
-
2642527240
-
Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)
-
Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004; 31: 265-267.
-
(2004)
Can J Neurol Sci
, vol.31
, pp. 265-267
-
-
Bakker, J.1
Metz, L.2
-
125
-
-
35448977649
-
Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica
-
Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007; 46: 1671-1672.
-
(2007)
Intern Med
, vol.46
, pp. 1671-1672
-
-
Okada, K.1
Tsuji, S.2
Tanaka, K.3
-
126
-
-
21644466723
-
Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment and prognosis
-
Stüve O, Nessler S, Hartung HP, et al. Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment and prognosis. Nervenarzt 2005; 76: 701-707.
-
(2005)
Nervenarzt
, vol.76
, pp. 701-707
-
-
Stüve, O.1
Nessler, S.2
Hartung, H.P.3
-
127
-
-
39449121111
-
Acute disseminated encephalomyelitis: Current understanding an controversies
-
Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis: current understanding an controversies. Semin Neurol 2008; 28: 84-94.
-
(2008)
Semin Neurol
, vol.28
, pp. 84-94
-
-
Young, N.P.1
Weinshenker, B.G.2
Lucchinetti, C.F.3
-
128
-
-
50549084831
-
High-dose, rapid infusion IVIG in postvaccination acute disseminated encephalomyelitis
-
Fu DC, Montgomery JR. High-dose, rapid infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology 2008; 71: 294-295.
-
(2008)
Neurology
, vol.71
, pp. 294-295
-
-
Fu, D.C.1
Montgomery, J.R.2
-
129
-
-
0033136412
-
Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis
-
Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999; 165: 56-61.
-
(1999)
J Neurol Sci
, vol.165
, pp. 56-61
-
-
Pradhan, S.1
Gupta, R.P.2
Shashank, S.3
Pandey, N.4
-
130
-
-
4644244150
-
Postinfectious and postvaccinal acute disseminated encephalomyelitis occuring in the same patients
-
Ravaglia S, Ceroni M, Moglia A, et al. Postinfectious and postvaccinal acute disseminated encephalomyelitis occuring in the same patients. J Neurol 2004; 251: 1147-1150.
-
(2004)
J Neurol
, vol.251
, pp. 1147-1150
-
-
Ravaglia, S.1
Ceroni, M.2
Moglia, A.3
-
131
-
-
36348972323
-
Severe steroid-resistant post-infectious encephalomyelitis: General features and effects of IVIg
-
Ravaglia S, Piccolo G, Ceroni M, et al. Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol 2007; 254: 1518-1523.
-
(2007)
J Neurol
, vol.254
, pp. 1518-1523
-
-
Ravaglia, S.1
Piccolo, G.2
Ceroni, M.3
-
132
-
-
1942518276
-
Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis associated with hepatitis A infection
-
Unay B, Sarici SU, Bulakbasi N, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis associated with hepatitis A infection. Pediatr Int 2004; 46: 171-173.
-
(2004)
Pediatr Int
, vol.46
, pp. 171-173
-
-
Unay, B.1
Sarici, S.U.2
Bulakbasi, N.3
-
133
-
-
34047230056
-
IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial
-
Zinman L Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 2007; 68: 837-841.
-
(2007)
Neurology
, vol.68
, pp. 837-841
-
-
Zinman, L.N.E.1
Bril, V.2
-
134
-
-
27744586691
-
Treatment of myasthenia gravis exacerbation with intravenous immunoglobulins
-
Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulins. Arch Neurol 2005; 62: 1689-1693.
-
(2005)
Arch Neurol
, vol.62
, pp. 1689-1693
-
-
Gajdos, P.1
Tranchant, C.2
Clair, B.3
-
136
-
-
33746534220
-
Guidelines for the treatment of autoimmune neuromuscular transmission disorders
-
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13: 691-699.
-
(2006)
Eur J Neurol
, vol.13
, pp. 691-699
-
-
Skeie, G.O.1
Apostolski, S.2
Evoli, A.3
-
137
-
-
0027729939
-
A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis
-
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
-
(1993)
N Engl J Med
, vol.329
, pp. 1993-2000
-
-
Dalakas, M.C.1
Illa, I.2
Dambrosia, J.M.3
-
138
-
-
70350572933
-
Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis
-
Danieli MG Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009; 9: 124-127.
-
(2009)
Autoimmun Rev
, vol.9
, pp. 124-127
-
-
Danieli, M.G.1
Calcabrini, L.2
Calabrese, V.3
-
139
-
-
39149128721
-
Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroidresistant polymyositis and dermatomyositis
-
Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroidresistant polymyositis and dermatomyositis. Mod Rheumatol 2008; 18: 34-44.
-
(2008)
Mod Rheumatol
, vol.18
, pp. 34-44
-
-
Saito, E.1
Koike, T.2
Hashimoto, H.3
-
140
-
-
0030947027
-
Treatment of inclusionbody myositis with IVIg: A double-blind, placebo-controlled study
-
Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusionbody myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-716.
-
(1997)
Neurology
, vol.48
, pp. 712-716
-
-
Dalakas, M.C.1
Sonies, B.2
Dambrosia, J.3
-
141
-
-
0035852876
-
A controlled study of IVIg combined with prednisone in the treatment of IBM
-
Dalakas MC, Koffman B, Fujii M, et al. A controlled study of IVIg combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-327.
-
(2001)
Neurology
, vol.56
, pp. 323-327
-
-
Dalakas, M.C.1
Koffman, B.2
Fujii, M.3
-
142
-
-
33846946820
-
Intravenous immune globulin in hereditary inclusion body myopathy: A pilot study
-
Sparks S, Rakocevic G, Joe G, et al. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurology 2007; 7: 3.
-
(2007)
BMC Neurology
, vol.7
, pp. 3
-
-
Sparks, S.1
Rakocevic, G.2
Joe, G.3
-
143
-
-
0035960860
-
High-dose intravenous immune globulin for stiff person syndrome
-
Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff person syndrome. N Engl J Med 2001; 345: 1870-1876.
-
(2001)
N Engl J Med
, vol.345
, pp. 1870-1876
-
-
Dalakas, M.C.1
Fujii, M.2
Li, M.3
-
144
-
-
0033825898
-
Successful immunoglobulin treatment in a patient with neuromyotonia
-
Alessi G, de Reuck J, De Bleecker J, et al. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg 2000; 102: 173-175.
-
(2000)
Clin Neurol Neurosurg
, vol.102
, pp. 173-175
-
-
Alessi, G.1
de Reuck, J.2
de Bleecker, J.3
-
145
-
-
33748978367
-
Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes
-
Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol 2006; 253(Suppl 5): 33-38.
-
(2006)
J Neurol
, vol.253
, Issue.SUPPL. 5
, pp. 33-38
-
-
Voltz, R.1
-
146
-
-
0029819742
-
Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome
-
Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47: 678-683.
-
(1996)
Neurology
, vol.47
, pp. 678-683
-
-
Bain, P.G.1
Motomura, M.2
Newsom-Davis, J.3
-
147
-
-
33746483826
-
Management of paraneoplastic neurological syndromes: Report of an EFNS Task Force
-
Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13: 682-690.
-
(2006)
Eur J Neurol
, vol.13
, pp. 682-690
-
-
Vedeler, C.A.1
Antoine, J.C.2
Giometto, B.3
-
148
-
-
0033942210
-
Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
-
Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93:433-439.
-
(2000)
Q J Med
, vol.93
, pp. 433-439
-
-
Jayne, D.R.1
Chapel, H.2
Adu, D.3
-
149
-
-
0029964713
-
Intravenous immunoglobulin as a sole therapy for systemic vasculitis
-
Jayne DR, Lockwood CM. Intravenous immunoglobulin as a sole therapy for systemic vasculitis. Br J Rheumatology 1996; 35: 1150-1153.
-
(1996)
Br J Rheumatology
, vol.35
, pp. 1150-1153
-
-
Jayne, D.R.1
Lockwood, C.M.2
-
150
-
-
0032728801
-
A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response
-
Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999; 8: 705-712.
-
(1999)
Lupus
, vol.8
, pp. 705-712
-
-
Levy, Y.1
Sherer, Y.2
Ahmed, A.3
-
151
-
-
0037431997
-
Benefit of IVIg for longstanding ataxic sensory neuronopathy with Sjögren's syndrome
-
Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIg for longstanding ataxic sensory neuronopathy with Sjögren's syndrome. Neurology 2003; 60: 503-505.
-
(2003)
Neurology
, vol.60
, pp. 503-505
-
-
Takahashi, Y.1
Takata, T.2
Hoshino, M.3
-
152
-
-
0035986913
-
Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis
-
Bien CG, Elger CE, Wiendl H. Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis. Expert Opin Invest Drugs 2002; 11: 981-989.
-
(2002)
Expert Opin Invest Drugs
, vol.11
, pp. 981-989
-
-
Bien, C.G.1
Elger, C.E.2
Wiendl, H.3
-
153
-
-
0036266629
-
The use of immunoglobulins in the treatment of human epilepsy
-
Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci 2002; 23(Suppl 1): 33-37.
-
(2002)
Neurol Sci
, vol.23
, Issue.SUPPL. 1
, pp. 33-37
-
-
Villani, F.1
Avanzini, G.2
-
154
-
-
73649096179
-
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies
-
Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009; 7: 337-342.
-
(2009)
Curr Neuropharmacol
, vol.7
, pp. 337-342
-
-
Jacob, S.1
Rajabally, Y.A.2
-
155
-
-
56549115782
-
Modulation of the cellular immune system by intravenous immunoglobulin
-
Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-615.
-
(2008)
Trends Immunol
, vol.29
, pp. 608-615
-
-
Tha-In, T.1
Bayry, J.2
Metselaar, H.J.3
-
156
-
-
0036884344
-
Immunomodulatory action of intravenous immunoglobulin
-
Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107: 387-393.
-
(2002)
Immunology
, vol.107
, pp. 387-393
-
-
Sewell, W.A.1
Jolles, S.2
-
157
-
-
0028026736
-
Intravenous immunoglobulins suppress immunoglobulin productiones by suppressing Ca2+-dependent signal transduction through Fc-gamma receptors in B lymphocytes
-
Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productiones by suppressing Ca2+-dependent signal transduction through Fc-gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37-42.
-
(1994)
Scand J Immunol
, vol.40
, pp. 37-42
-
-
Kondo, N.1
Kasahara, K.2
Kameyama, T.3
-
158
-
-
0025844927
-
Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin
-
Kondo N, Ozawa T, Mushiake K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11: 152-158.
-
(1991)
J Clin Immunol
, vol.11
, pp. 152-158
-
-
Kondo, N.1
Ozawa, T.2
Mushiake, K.3
-
159
-
-
0027189640
-
Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)
-
Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993; 92: 369-372.
-
(1993)
Clin Exp Immunol
, vol.92
, pp. 369-372
-
-
Vassilev, T.1
Gelin, C.2
Kaveri, S.V.3
-
160
-
-
0028945912
-
In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins
-
Toungouz M, Denys CH, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89: 698-703
-
(1995)
Br J Haematol
, vol.89
, pp. 698-703
-
-
Toungouz, M.1
Denys, C.H.2
de Groote, D.3
Dupont, E.4
-
161
-
-
0023692759
-
Antineuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: Inhibition in vitro and in vivo bei IV immunoglobulin
-
van Doorn PA, Brand A, Vermeulen M. Antineuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: Inhibition in vitro and in vivo bei IV immunoglobulin. Neurology 1988; 38: 1592-1595.
-
(1988)
Neurology
, vol.38
, pp. 1592-1595
-
-
van Doorn, P.A.1
Brand, A.2
Vermeulen, M.3
-
162
-
-
0027193506
-
Spontaneous recovery from the Guillain-Barré-Syndrome is associated with antiidiotypic antibodies recognizing a cross-reactive idiotype on antineuroblastoma cell line antibodies
-
Lundkvist I, van Doorn PA, Vermeulen M, et al. Spontaneous recovery from the Guillain-Barré-Syndrome is associated with antiidiotypic antibodies recognizing a cross-reactive idiotype on antineuroblastoma cell line antibodies. Clin Immunol Immunopathol. 1993; 67: 192-198.
-
(1993)
Clin Immunol Immunopathol
, vol.67
, pp. 192-198
-
-
Lundkvist, I.1
van Doorn, P.A.2
Vermeulen, M.3
-
163
-
-
0030070677
-
Intravenous gamma- Globulin inhibits binding of anti-GM1 to its target antigen
-
Malik U, Oleksowicz L, Latov N, et al. Intravenous gamma- Globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996; 39: 136-139.
-
(1996)
Ann Neurol
, vol.39
, pp. 136-139
-
-
Malik, U.1
Oleksowicz, L.2
Latov, N.3
-
164
-
-
0028025519
-
Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use
-
Caccavo D, Vaccaro F, Ferri GM, et al. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 1994; 7: 537-548.
-
(1994)
J Autoimmun
, vol.7
, pp. 537-548
-
-
Caccavo, D.1
Vaccaro, F.2
Ferri, G.M.3
-
165
-
-
0033590571
-
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
-
Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-228.
-
(1999)
N Engl J Med
, vol.340
, pp. 227-228
-
-
Yu, Z.1
Lennon, V.A.2
-
166
-
-
0028928224
-
Inhibition of complement- mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties
-
Mollnes TE, Høgåsen K, Hoaas BF, et al. Inhibition of complement- mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol 1995; 41: 449-456.
-
(1995)
Scand J Immunol
, vol.41
, pp. 449-456
-
-
Mollnes, T.E.1
Høgåsen, K.2
Hoaas, B.F.3
-
167
-
-
0026343758
-
The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues
-
Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62: S82-S86.
-
(1992)
Clin Immunol Immunopathol
, vol.62
-
-
Frank, M.M.1
Basta, M.2
Fries, L.F.3
-
168
-
-
0029900936
-
High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
-
Lutz HU, Stammler P, Jelezarova E, et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-193.
-
(1996)
Blood
, vol.88
, pp. 184-193
-
-
Lutz, H.U.1
Stammler, P.2
Jelezarova, E.3
-
169
-
-
10744224652
-
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins
-
Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431-438.
-
(2003)
Nat Med
, vol.9
, pp. 431-438
-
-
Basta, M.1
van Goor, F.2
Luccioli, S.3
-
170
-
-
0026591031
-
Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain
-
Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89: 3325-3329.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 3325-3329
-
-
Marchalonis, J.J.1
Kaymaz, H.2
Dedeoglu, F.3
-
171
-
-
0030019996
-
Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use
-
Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-869.
-
(1996)
J Clin Invest
, vol.97
, pp. 865-869
-
-
Kaveri, S.1
Vassilev, T.2
Hurez, V.3
-
172
-
-
0035877164
-
Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1
-
Bouhlal H, Hocini H, Quillent-Grégoire C, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166: 7606-7611.
-
(2001)
J Immunol
, vol.166
, pp. 7606-7611
-
-
Bouhlal, H.1
Hocini, H.2
Quillent-Grégoire, C.3
-
174
-
-
0031687191
-
Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: A possible mechanism of action in vascular diseases
-
Xu C, Poirier B, Duong Van Huyen JP, et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol. 1998; 153: 1257-1266.
-
(1998)
Am J Pathol
, vol.153
, pp. 1257-1266
-
-
Xu, C.1
Poirier, B.2
van Huyen, D.J.P.3
-
175
-
-
10344264520
-
IVIg therapy in brain inflammation: Etiology-dependent differential effects on leucocyte recruitment
-
Lapointe BM, Herx LM, Gill V, et al. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004; 127: 2649-2656.
-
(2004)
Brain
, vol.127
, pp. 2649-2656
-
-
Lapointe, B.M.1
Herx, L.M.2
Gill, V.3
-
176
-
-
0033152251
-
Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)
-
Vassilev TL, Kazatchkine MD, Duong Van Huyen JP, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93: 3624-3631.
-
(1999)
Blood
, vol.93
, pp. 3624-3631
-
-
Vassilev, T.L.1
Kazatchkine, M.D.2
van Huyen, D.J.P.3
-
177
-
-
0028080751
-
Promotion of remyelination by polyclonal immunoglobulin in Theiler's virusinduced demyelination and in multiple sclerosis
-
van Engelen BG, Miller DJ, Pavelko KD, et al. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virusinduced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57 (Suppl): 65-68.
-
(1994)
J Neurol Neurosurg Psychiatry
, vol.57
, Issue.SUPPL.
, pp. 65-68
-
-
van Engelen, B.G.1
Miller, D.J.2
Pavelko, K.D.3
-
178
-
-
33947535936
-
Effectors of demyelination and remyelination in the CNS: Implications for multiple sclerosis
-
Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 2007; 17: 219-229.
-
(2007)
Brain Pathol
, vol.17
, pp. 219-229
-
-
Rodriguez, M.1
-
179
-
-
0030753782
-
Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases
-
Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerv 1997; 20:1102-1107.
-
(1997)
Muscle Nerv
, vol.20
, pp. 1102-1107
-
-
Koffman, B.M.1
Dalakas, M.C.2
-
180
-
-
0037903158
-
Arterial thrombosis induced by IVIg and its treatment with tPA
-
Okuda D, Flaster M, Frey J, Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 2003; 60: 1825-1826.
-
(2003)
Neurology
, vol.60
, pp. 1825-1826
-
-
Okuda, D.1
Flaster, M.2
Frey, J.3
Sivakumar, K.4
-
181
-
-
0038240601
-
The clinical features of 16 cases of stroke associated with administration of IVIg
-
Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003; 60: 1822-1824.
-
(2003)
Neurology
, vol.60
, pp. 1822-1824
-
-
Caress, J.B.1
Cartwright, M.S.2
Donofrio, P.D.3
Peacock Jr., J.E.4
|